On November 27, 2024, Fosun Pharmaceutical announced that its holding subsidiary Shanghai Xiastar Pharmaceutical has received approval from the National Medical Products Administration for injectable type A botulinum toxin to treat a new indication of adult focal dystonia. The product was previously approved by the FDA in the United States for improving symptoms such as glabellar lines in adults. Since 2018, the company has partnered with Revance Therapeutics, Inc. to obtain exclusive rights for the import, use, and commercialization of the product in mainland China, Hong Kong, and Macau. As of October 2024, Fosun Pharmaceutical has invested approximately 487 million RMB in the research and development of this product. According to IQVIA data, the global sales of injectable type A botulinum toxin were about 2.46 billion USD in 2023. The approval of this new indication is expected to further enhance the competitiveness and sales potential of the product in the Chinese market.

On November 27, 2024, Fosun Pharmaceutical announced that its holding subsidiary Shanghai Xiastar Pharmaceutical has received approval from the National Medical Products Administration for injectable type A botulinum toxin to treat a new indication of adult focal dystonia. The product was previously approved by the FDA in the United States for improving symptoms such as glabellar lines in adults. Since 2018, the company has partnered with Revance Therapeutics, Inc. to obtain exclusive rights for the import, use, and commercialization of the product in mainland China, Hong Kong, and Macau. As of October 2024, Fosun Pharmaceutical has invested approximately 487 million RMB in the research and development of this product. According to IQVIA data, the global sales of injectable type A botulinum toxin were about 2.46 billion USD in 2023. The approval of this new indication is expected to further enhance the competitiveness and sales potential of the product in the Chinese market.